Pfizer Inc. PFE, -0.18% plans to acquire cancer biotechnology company Seagen Inc. SGEN, -0.59% in a deal with a $43 billion enterprise value, the companies announced Monday morning. Pfizer intends to ...
Tag: PFE
Novavax Says ‘Substantial Doubt’ Around Its Continuing Operations
Covid-19 vaccine manufacturer Novavax said Tuesday that there is “substantial doubt” about its ability to continue operating through this year. In a quarterly earnings report issued after the market c...
Pfizer CEO: Covid Infections Will Rise. So Will Paxlovid and Vaccine Sales.
Pfizer executives say Wall Street analysts haven’t understood just how powerful a hit the company’s Covid-19 products will take this year. That’s the explanation the company’s chief financial officer,...
Pfizer (PFE) Q4 earnings 2022
Vials containing the Pfizer/BioNtech vaccine against the coronavirus disease (COVID-19) are displayed before being used at a mobile vaccine clinic, in Valparaiso, Chile, January 3, 2022. Rodrigo Garri...
With Pfizer Firmly in Value Territory, Here’s What Investors Are Missing
Investors have faced a conundrum in valuing companies that benefited from the Covid-19 pandemic. Pfizer’s (PFE) partnership with BioNTech (BNTX) in creating a vaccine, plus its antiviral, Paxlov...
Pfizer, Unum Group And Signature Bank
On 1/26/23, Pfizer, Unum Group, and Signature Bank will all trade ex-dividend for their respective upcoming dividends. Pfizer Inc will pay its quarterly dividend of $0.41 on 3/3/23, Unum Group will pa...
Tanking Biotech Stocks Will Mean a Big Year for Deals. Who Could Benefit.
Nearly two years after biotechnology stocks began to tumble, executives at small and midsize companies in the space are finally accepting that share prices aren’t bouncing back anytime soon. With real...
It’s Pharma Time: Why Merck and Lilly Stock Are Buys, but not Pfizer.
My 2023 biotech outlook calls for continued momentum in name changes. I just need to figure out what the stocks will do. Last year, Respira Technologies became Qnovia. It’s run by a former tobacco exe...
Will Pfizer Share Price (NYSE: PFE) Sustain above $50? – Quarterly Growth Shines by 15%
Pfizer Share price has showcased some promising trading factors as it crossed 16% growth rate during this quarter. Pfizer Inc. (NYSE: PFE) is up 41% in the last five years, also slightly above the mar...
Stock Market Looks Poised to Rally as Bond Yield Falls
Text size Michael Nagle/Bloomberg The worst may be over for the stock market. Key equity indexes continued their autumn rally, and there could be more gains before the end of the year, helped by conti...
Pfizer Stock’s Post-Covid Future Looks Healthy
These reports, excerpted and edited by Barron’s, were issued recently by investment and research firms. The reports are a sampling of analysts’ thinking; they should not be considered the views or rec...
Pfizer CEO Shares Companies Future Plans, Surely Affecting PFE Stock Price
Pfizer emerged as a prominent name as producer of Covid-19 vaccines and PFE stocks reflected good growth American multinational pharmaceutical company Pfizer (PFE) has new plans to diversify its produ...
Moderna Stock Takes Off on Cancer Vaccine News
Moderna stock shot up after Merck said it is exercising an option to work on a personalized cancer vaccine with the Covid-19 vaccine maker. Merck (ticker: MRK) will pay Moderna (MRNA) $250 million for...
CVS Is in Advanced Talks to Buy Signify Health for Around $8 Billion
CVS Health is in advanced talks to acquire the home-healthcare company Signify Health for around $8 billion, according to people familiar with the matter. CVS appears to have beat out other heavy hitt...
10 defensive stocks that can also provide you with growth and dividends over the long term
The S&P 500 Index has rallied 10% since June 22 from a deep decline, but there are different schools of thought about whether investors are out of the woods yet. Mark Hulbert has called the recent...
Pfizer in Advanced Talks to Buy Global Blood Therapeutics for About $5 Billion
Pfizer is in advanced talks to buy Global Blood Therapeutics the maker of a recently approved drug for sickle-cell disease, for about $5 billion, in the latest move by the drug giant to bolster its po...
A Recession Is Coming. These Are the Stocks to Hunker Down In.
Eli Salzmann loves nothing better than finding a company that’s a “dog of a stock with no momentum” but on the verge of better days. At its core, that is what value investing is all about. Over the co...
Moderna CEO: No ‘Crazy’ Deals. We’re Giving Cash to Shareholders.
Text size Moderna CEO Stephane Bancel says his company will keep returning cash to investors until it finds a better way of creating value. Jason Alden/Bloomberg Moderna ’s CEO is feeling no pressure ...
Moderna’s Earnings Are Wednesday. Here’s What to Expect.
Text size Moderna is developing two vaccines for the fall, one for the U.S. and the other for international markets. Sean Gallup/Getty Images As the U.S. prepares for a broad Covid-19 booster campaign...
What investors need to know about Pfizer’s latest downgrade
Pfizer’s PFE, -0.92% early-stage pipeline, though promising, is still too premature to make up for the looming loss of billions of dollars from the company’s COVID-19 franchise, which includes the vac...